References
- Verbij FC, Fijnheer R, Voorberg J, et al. Acquired TTP: ADAMTS13 meets the immune system. Blood Rev. 2014;28:227–234.
- Schapkaitz E, Schickerling TM. The diagnostic challenge of acquired thrombotic thrombocytopenic purpura in children: case report and review of the literature. Lab Med. 2018;49:268–271.
- Reese JA, Muthurajah DS, Kremer Hovinga JA, et al. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013;60:1676–1682.
- Cataland SR, Wu HM. Acquired thrombotic thrombocytopenic purpura: new therapeutic options and their optimal use. J Thromb Haemost. 2015;13:S223–9.
- Tonaco LC, Rios DRA, Vieira LM, et al. Thrombotic thrombocytopenic purpura: the role of von Willebrand factor and ADAMTS13. Rev Bras Hematol Hemoter. 2010;32:155–161.
- Knöbl P. Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost. 2014;40:493–502.
- Pereira A, Mazzara R, Monteagudo J, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange. Ann Hematol. 1995;70:319–323.
- Miesbach W, Menne J, Bommer M, et al. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study. Orphanet J Rare Dis. 2019;14:260.
- Orphanet: immune-mediated thrombotic thrombocytopenic purpura [Internet]. portal rare Dis. orphan drugs; 2020 [updated 2021 Feb 8; cited 2021 Feb 8]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=93585
- Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142:819–826.
- Velasco-Pedro P, Buitrago N, Gonzalez D. Caso clínico Púrpura Trombocitopénica Trombótica: diagnóstico diferencial con El Síndrome hemolítico urémico. Cimel. 2015;20:20–24.
- Aryal M, Pathak R, Giri S, et al. Recent trends in the incidence and outcomes of thrombotic thrombocytopenic purpura in the United States: data from the 2009–2014 national inpatient sample. Blood. 2017;130:2086.
- Pollissard L, Shah A, Punekar RS, et al. Burden of illness among medicare and non-medicare US populations with acquired thrombotic thrombocytopenic purpura. J Med Econ. 2021;24:706–716.
- Tsai HM. Thrombotic thrombocytopenic purpura: beyond empiricism and plasma exchange. Am J Med. 2019;132:1032–1037.
- Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335.
- Verbraecken J, Van de Heyning P, De Backer W, et al. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism. 2006;55:515–524.
- Ministerio de Salud y Protección Social. Encuesta Nacional de la Situación Nutricional en Colombia -ENSIN 2015;2020. Accessed 23 12 2021. https://www.icbf.gov.co/bienestar/nutricion/encuesta-nacional-situacion-nutricional#ensin3.
- Page EE, Kremer Hovinga JA, Terrell DR, et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1:590–600.
- Mancini I, Pontiggia S, Palla R, et al. Clinical and laboratory features of patients with acquired thrombotic thrombocytopenic purpura: fourteen years of the milan TTP registry. Thromb Haemost. 2019;119:695–704.
- Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–346.
- Rohatgi A. WebPlotDigitizer: HTML5 based online tool to extract numerical data from plot images. Version 4.2. California [Internet]; 2018. Accessed 23 12 2021. Available from: https://automeris.io/WebPlotDigitizer.
- Peigne V, Perez P, Resche Rigon M, et al. Causes and risk factors of death in patients with thrombotic microangiopathies. Intensive Care Med. 2012;38:1810–1817. •• informs differences in survival curves in plasma exchange vs no plasma exchange.
- Rock GA, Shumak KH, Buskard NA. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Ann Int Med N Engl J Med. 1991;325 :81.
- National Institute for Health and Care Excellence (NICE). Single technology appraisal caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185] [Internet]; 2020 [cited 2020 Nov 10]. Available from: https://www.nice.org.uk/guidance/gid-ta10361/documents/committee-papers
- Ministerio de Salud y Protección Social (MSPS). Sismed - Sistema de información de precios de medicamentos. Reporte 2020. [Internet]; 2021 [cited 2021 Apr 10]. Available from: http://www.sispro.gov.co/recursosapp/app/Pages/PreciosdeMedicamentos-Circular2de2012Excel.aspx
- Ministerio de Salud y de la Proteccion Social. Circular 10 de 2020. Por la cual se unifica y se adiciona el listado de los medicamentos sujetos al régimen de control directo de precios, se fija su precio máximo de venta, se actualiza el precio de algunos medicamentos conforme al Índice de precios [Internet]; 2020 [cited 2021 Apr 10]. Available from: http://minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/MET/circular-10-de-2020.pdf
- Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int. 1990;38:160–166.
- Chiasakul T, Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol. 2018;2018:530–538.
- Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. Morty RE, editor. PLoS One. 2010;5:e10208.
- Ministerio de Salud y Protección Social. Ley 1392 de 2010. Por medio de la cual se reconocen las enfermedades huérfanas como de especial interés y se adoptan normas tendientes a garantizar la protección social por parte del estado colombiano a la población que padece de enfermedades huérfanas y [Internet]; 2010. Accessed 23 12 2021. Available from: https://www.minsalud.gov.co/salud/publica/PENT/Paginas/enfermedades-huerfanas.aspx
- Ministerio de Salud y Protección Social. Resolución 5265 de 2018: por la cual se actualiza el listado de enfermedades huérfanas y se dictan otras disposiciones [Internet]; 2018. Accessed 23 12 2021. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/resolucion-5265-de-2018.pdf
- Ministerio de Salud y Protección Social. Listado de patologías postuladas para la inclusión en el listado de enfermedades huérfanas [Internet]; 2017 [cited 2021 Mar 16]. Available from: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/listado-patologias-postualdas-enfermedaes-huerfanas.pdf
- Cárdenas Roldán J. Cuando todo no es suficiente. Acta Méd Colomb. 2019;43:33–35.